Navigation Links
MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
Date:1/30/2008

ization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front- loaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(TM). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more on MiddleBrook, please visit http://www.middlebrookpharma.com.

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on MiddleBrook's current expectations and assumptions. These statements are not guarantees of future performance and are subject to a number of risks and uncertainties that would cause actual results to differ materially from those anticipated. The words, "believe," "expect," "intend," "anticipate," and variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward- looking. Statements in this announcement that are forward-looking include, but are not limited to, statements about the Company's future development plans, clinical trials, potential commercial success, and any financial forecasts included in this announcement.

The actual results realized by MiddleBrook could differ materially from these forward-looking statements, depending in particular upon the risks and uncertainties described in the Company's fil
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Access Pharmaceuticals Announces $2.7 Million New Equity
3. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
4. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
5. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
6. Onyx Pharmaceuticals to Present at Wachovia Healthcare Conference
7. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
8. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
9. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
10. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
11. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... VIENNA , October 20, 2014 ... of gastrointestinal (GI) disorders and the delivery of care ... liver diseases and worrying inequalities in the provision of ... survey, which was commissioned by United European Gastroenterology (UEG), ... greater political and public awareness of the burden of ...
(Date:10/20/2014)... Earle Martin , Chief ... that Ellen Teplitzky, an experienced attorney specializing in ... industry, has joined the firm as Director of ... practice. NDA Partners provides legal services, including ... to top law firms and their clients in ...
(Date:10/19/2014)... Oct. 19, 2014 NextCODE Health, which enables clinicians ... in real time, today announced the launch of its new ... , at the American Society of Human Genetics (ASHG) annual ... more, sign up and apply for free beta access, visit ... and benefits can be viewed here . ...
(Date:10/19/2014)... The report "Chocolate, Cocoa Beans, Lecithin, Sugar and ... and Forecast (2011 - 2016)," analyzes the chocolate ... the major market drivers, restraints, and opportunities for the ... The global chocolate market is expected to grow from ... an estimated CAGR of 2.7% from 2011 to 2016. ...
Breaking Biology Technology:Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... ... capabilities for Mass Spectrometry-based biomarker discovery will be demonstrated at the 57th ASMS Conference ... Convention Center. , ... Philadelphia, PA (PRWEB) June 1, 2009 -- Genedata , a leading provider of ...
... , - Results Presented at American Society of Clinical ... Tolerated with Favorable Pharmacokinetics and Prolonged Stable Disease in ... 1 Mersana Therapeutics presented preliminary results of a ... XMT-1001, in a poster session at the 2009 Annual ...
... Webinar on June 9 to discuss the prevalence and prevention ... www.connecttoprotect.com - , , BETHESDA, ... (AGA) Institute and Horizon Therapeutics, Inc. today launched Connect ... gastrointestinal (GI) risks associated with the use of non-steroidal anti-inflammatory ...
Cached Biology Technology:Genedata Launches Expressionist with Expanded Mass Spectrometry Biomarker Discovery Capabilities 2Genedata Launches Expressionist with Expanded Mass Spectrometry Biomarker Discovery Capabilities 3Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors 2Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors 3AGA Institute and Horizon Therapeutics Launch 'Connect to Protect' Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 2AGA Institute and Horizon Therapeutics Launch 'Connect to Protect' Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 3
(Date:10/15/2014)... The German Gauß-Allianz has admitted Johannes Gutenberg University ... the Rhineland-Palatinate science hub continues to maintain a ... computing. , "The acceptance of Johannes Gutenberg ... Gauß-Allianz is a milestone in the national and ... support. The state of Rhineland-Palatinate can be proud ...
(Date:10/15/2014)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" or ... commerce market releases photos and video of the recent opening bell ... th . Gino Pereira , CEO of ... Mr. Chad A. Verdi rang the bell.  ... and employees "for their work and dedication in bringing the world,s ...
(Date:10/14/2014)... – Like discriminating thieves, prostate cancer tumors scavenge and ... body. But such avarice may be a fatal weakness. ... way to kill prostate cancer cells by delivering a ... destroys the diseased cells brimming with the mineral, leaving ... two drugs already commercially available for other uses, could ...
Breaking Biology News(10 mins):Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Prostate cancer's penchant for copper may be a fatal flaw 2
... gene may be an early step in the development of ... this inactivation may ultimately be useful in risk assessment for ... 21 issue of the Journal of the National Cancer ... cells with a "field defect", cells that appear normal but ...
... Human Genome Research Institute (NHGRI), one of the National ... Sequencing Research Network will target 13 more organisms as ... that will expand biological knowledge and improve human health. ... (NACHGR), which is a federally chartered committee that advises ...
... Nanostructured micro-devices may be mass produced at a ... shapes and compositions than ever before, for dramatic ... biologically produced structures. These entirely new biologically-enabled approaches ... International Journal of Applied Ceramic Technology, published on ...
Cached Biology News:Change in gene may be underlying molecular defect in some colorectal cancers 2Possible treatment found for 'chemobrain' 2Possible treatment found for 'chemobrain' 3Possible treatment found for 'chemobrain' 4Possible treatment found for 'chemobrain' 5